Single-cell RNA sequencing to identify cellular heterogeneity and targets in cardiovascular diseases: from bench to bedside
X Xu, X Hua, H Mo, S Hu, J Song - Basic research in cardiology, 2023 - Springer
The mechanisms of cardiovascular diseases (CVDs) remain incompletely elucidated. Single-
cell RNA sequencing (scRNA-seq) has enabled the profiling of single-cell transcriptomes at …
cell RNA sequencing (scRNA-seq) has enabled the profiling of single-cell transcriptomes at …
BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
J Fang, F Zhou - Annals of Hematology, 2024 - Springer
Recently, many new therapies have improved the outcomes of patients with relapsed and/or
refractory multiple myeloma (RRMM). Nevertheless, recurrence is still unavoidable, and …
refractory multiple myeloma (RRMM). Nevertheless, recurrence is still unavoidable, and …
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow
microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase …
microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase …
Normalization of the immunological microenvironment and sustained minimal residual disease negativity: do we need both for long-term control of multiple myeloma?
G Bertuglia, L Cani, A Larocca, F Gay… - International Journal of …, 2022 - mdpi.com
Over the past two decades, the treatment landscape for multiple myeloma (MM) has
progressed significantly, with the introduction of several new drug classes that have greatly …
progressed significantly, with the introduction of several new drug classes that have greatly …
[PDF][PDF] Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
N Grieb, R Weiss, J Sia, L Fischer, P Born, A Boldt… - 2023 - backoffice.biblio.ugent.be
Introduction: Robust biomarkers of response and resistance to chimeric antigen receptor
(CAR) T cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) are …
(CAR) T cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) are …
[PDF][PDF] " Multimodal Immunomonitoring of Hematopoietic Stem Cell Transplantation and Cellular Therapies for Hematological Malignancies
F SIMONETTA - access.archive-ouverte.unige.ch
Allogeneic hematopoietic stem cell transplantation (HSCT) and other cellular therapies are a
broadly used therapeutic strategy employed against a wide range of hematological …
broadly used therapeutic strategy employed against a wide range of hematological …